Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The company operates within the biopharmaceutical and regenerative medicine industries and generates the majority of its revenue from proprietary PAH therapies marketed globally. Its core products include prostacyclin pathway therapies and vasodilators designed to improve survival and quality of life for patients with rare and chronic conditions.
Founded in 1996, the company was established to commercialize treatments for PAH and has since expanded its scope to include organ manufacturing technologies aimed at addressing the shortage of transplantable organs. United Therapeutics is known for its vertically integrated model that combines drug development, device innovation, and biologics manufacturing. A distinguishing strategic feature is its long-term investment in xenotransplantation and bioengineered organ platforms, positioning the company beyond traditional biopharmaceutical competitors.
Business Operations
United Therapeutics operates primarily through its Pulmonary Hypertension business segment, which includes marketed therapies such as Remodulin, Tyvaso, Orenitram, and Adcirca, generating the majority of company revenue. These products are sold through specialty pharmacy distribution models, primarily in the United States, with additional international sales through partners and subsidiaries. Revenue is driven by chronic-use therapies, providing recurring income tied to long-term patient treatment.
In addition to commercial pharmaceuticals, the company maintains research and development operations focused on next-generation drug delivery systems, regenerative medicine, and organ replacement technologies. Key subsidiaries include Lung Biotechnology PBC, which focuses on organ manufacturing and xenotransplantation, and Miromatrix Medical Inc., in which the company holds a significant equity interest related to bioengineered organs. The company also controls proprietary manufacturing facilities and logistics infrastructure supporting both clinical and commercial supply chains.
Strategic Position & Investments
Strategically, United Therapeutics prioritizes lifecycle management of its PAH franchise while investing heavily in transformative technologies aimed at long-term growth. Growth initiatives include label expansions, new formulations, and device-enabled delivery platforms such as dry powder inhalation systems. The company has also made substantial capital investments in regenerative medicine, particularly in gene-edited pig organ development for human transplantation.
Major investments include majority ownership of Lung Biotechnology PBC and significant funding of xenotransplantation research programs and organ preservation technologies. United Therapeutics has completed multiple acquisitions and equity investments to support this strategy, including Miromatrix Medical Inc., which focuses on decellularized and recellularized organs. These initiatives place the company at the intersection of biotechnology, medical devices, and advanced biologics manufacturing.
Geographic Footprint
United Therapeutics is headquartered in Silver Spring, Maryland, United States, and conducts the majority of its commercial operations in North America, which represents its largest revenue-generating region. The company maintains additional operational and research facilities across the United States, including manufacturing, logistics, and research campuses supporting both pharmaceuticals and regenerative medicine initiatives.
Internationally, United Therapeutics has a presence in Europe, Asia-Pacific, and parts of Latin America through subsidiaries and commercial partnerships. Its therapies are marketed in multiple countries, with international revenue contributing a smaller but consistent portion of total sales. The company’s global footprint also includes international clinical trials and collaborative research efforts related to organ manufacturing and transplantation technologies.
Leadership & Governance
United Therapeutics was founded by Martine Rothblatt, whose vision emphasized patient-centered innovation and long-term investment in transformative medical solutions. The company is led by a management team with deep experience in biotechnology, regulatory affairs, and pharmaceutical commercialization, and it maintains a governance structure that supports significant reinvestment into research and development.
Key executives include:
- Martine Rothblatt – Executive Chairperson
- Michael Benkowitz – Chief Executive Officer
- James Edgemond – President and Chief Operating Officer
- Paul A. Mahon – Executive Vice President and General Counsel
- Eric M. Medel – Chief Financial Officer
Leadership philosophy centers on sustained innovation, disciplined capital allocation, and addressing unmet medical needs, particularly in rare diseases and organ failure, with a long-term strategic horizon rather than short-term market optimization.